Anavex Life Sciences Stock Earnings Reports

Anavex updated investors on clinical, regulatory, financial and commercialization progress. Key clinical highlights: open-label extension data for oral blarcamesine (ANAVEX2-73) showed continued, clinically meaningful benefit in early Alzheimer’s patients over three to four years as measured by ADAS-Cog13 and ADCS-ADL. The company’s EMA submission for blarcamesine was accepted (submission in November, accepted December) and management expects regulatory feedback in roughly a 12-month timeframe (potentially by year-end or early next quarter). In schizophrenia, enrollment for the Phase 2 ANAVEX3-71 study is complete (71 participants: 16 in Part A, 55 in Part B); Part B is a 28-day randomized cohort and topline data are expected in H2 2025. Commercial readiness is underway with partner and CRO discussions in Europe and plans to engage other regulators (UK, Canada, Australia) in parallel. Financials: cash of $115.8M as of March 31, no debt, cash burn ~$5.9M for the quarter, net loss $11.2M (Q2 FY2025), and management estimates a cash runway of approximately four years at current burn. Other notes: expanded scientific advisory board and available launch inventory manufactured by a large U.S. contract manufacturer.